173 related articles for article (PubMed ID: 33526602)
1. Oncologist-led
Yoon SY; Wong SW; Lim J; Ahmad S; Mariapun S; Padmanabhan H; Hassan NT; Lau SY; Ch'ng GS; Haniffa M; Ong WP; Rethanavelu K; Moey LH; Keng WT; Omar J; Mohd Abas MN; Yong CM; Ramasamy V; Md Noor MR; Aliyas I; Lim MCK; Suberamaniam A; Mat Adenan NA; Ahmad ZA; Ho GF; Abdul Malik R; Subramaniam S; Khoo BP; Raja A; Chin YS; Sim WW; Teh BH; Kho SK; Ong ESE; Voon PJ; Ismail G; Lee CL; Abdullah BZ; Loo KS; Lim CS; Lee SJ; Lim KJL; Shafiee MN; Ismail F; Latiff ZA; Ismail MP; Mohamed Jamli MF; Kumarasamy S; Leong KW; Low J; Md Yusof M; Ahmad Mustafa AM; Mat Ali NH; Makanjang M; Tayib S; Cheah N; Lim BK; Fong CK; Foo YC; Mellor Abdullah M; Tan TS; Chow DSY; Ho KF; Raman R; Radzi A; Deniel A; Teoh DCY; Ang SF; Joseph JK; Ng PHO; Tho LM; Ahmad AR; Muin I; Bleiker E; George A; Thong MK; Woo YL; Teo SH
J Med Genet; 2022 Mar; 59(3):220-229. PubMed ID: 33526602
[TBL] [Abstract][Full Text] [Related]
2. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
Colombo N; Huang G; Scambia G; Chalas E; Pignata S; Fiorica J; Van Le L; Ghamande S; González-Santiago S; Bover I; Graña Suárez B; Green A; Huot-Marchand P; Bourhis Y; Karve S; Blakeley C
J Clin Oncol; 2018 May; 36(13):1300-1307. PubMed ID: 29558274
[TBL] [Abstract][Full Text] [Related]
4. Attitudes and training needs of oncologists and surgeons in mainstreaming breast cancer genetic counseling in a low-to-middle income Asian country.
Lee YQ; Yoon SY; Hassan T; Padmanabhan H; Yip CH; Keng WT; Thong MK; Ahmad Annuar MA; Mohd Taib NA; Teo SH
J Genet Couns; 2022 Oct; 31(5):1080-1089. PubMed ID: 35481858
[TBL] [Abstract][Full Text] [Related]
5.
Kansu B; Gardner J; Price-Tate R; Murch O; Murray A
J Obstet Gynaecol; 2021 Aug; 41(6):962-965. PubMed ID: 33228436
[TBL] [Abstract][Full Text] [Related]
6. Uptake of testing for germline
Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
[TBL] [Abstract][Full Text] [Related]
7. Finding all BRCA pathogenic mutation carriers: best practice models.
Hoogerbrugge N; Jongmans MC
Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
[TBL] [Abstract][Full Text] [Related]
8. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
Kentwell M; Dow E; Antill Y; Wrede CD; McNally O; Higgs E; Hamilton A; Ananda S; Lindeman GJ; Scott CL
Gynecol Oncol; 2017 Apr; 145(1):130-136. PubMed ID: 28162234
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
10. Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
Rahman B; Lanceley A; Kristeleit RS; Ledermann JA; Lockley M; McCormack M; Mould T; Side L
J Med Genet; 2019 Mar; 56(3):195-198. PubMed ID: 29535157
[TBL] [Abstract][Full Text] [Related]
11. Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
Rumford M; Lythgoe M; McNeish I; Gabra H; Tookman L; Rahman N; George A; Krell J
Sci Rep; 2020 Feb; 10(1):3390. PubMed ID: 32098980
[TBL] [Abstract][Full Text] [Related]
12.
Piedimonte S; Power J; Foulkes WD; Weber E; Palma L; Schiavi A; Ambrosio E; Konci R; Gilbert L; Jardon K; Baret L; Zeng X
Int J Gynecol Cancer; 2020 Nov; 30(11):1757-1761. PubMed ID: 32759180
[TBL] [Abstract][Full Text] [Related]
13. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
Tutty E; Petelin L; McKinley J; Young MA; Meiser B; Rasmussen VM; Forbes Shepherd R; James PA; Forrest LE
Eur J Hum Genet; 2019 Aug; 27(8):1186-1196. PubMed ID: 30962500
[TBL] [Abstract][Full Text] [Related]
15. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N
Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053
[TBL] [Abstract][Full Text] [Related]
16. Referral of Ovarian Cancer Patients for Genetic Counselling by Oncologists: Need for Improvement.
Ricci MT; Sciallero S; Mammoliti S; Gismondi V; Franiuk M; Bruzzi P; Varesco L
Public Health Genomics; 2015; 18(4):225-32. PubMed ID: 26111740
[TBL] [Abstract][Full Text] [Related]
17. Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
Powell CB; Laurent C; Ciaravino G; Garcia C; Han L; Hoodfar E; Karlea A; Kobelka C; Lee J; Littell RD; Roh J; Vay A; Kushi LH
Gynecol Oncol; 2020 Oct; 159(1):221-228. PubMed ID: 32778409
[TBL] [Abstract][Full Text] [Related]
18. The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
Gleeson M; Kentwell M; Meiser B; Do J; Nevin S; Taylor N; Barlow-Stewart K; Kirk J; James P; Scott CL; Williams R; Gamet K; Burke J; Murphy M; Antill YC; Pearn A; Pachter N; Ebzery C; Poplawski N; Friedlander M; Tucker KM;
Gynecol Oncol; 2020 Aug; 158(2):431-439. PubMed ID: 32451123
[TBL] [Abstract][Full Text] [Related]
19. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
McCuaig JM; Stockley TL; Shaw P; Fung-Kee-Fung M; Altman AD; Bentley J; Bernardini MQ; Cormier B; Hirte H; Kieser K; MacMillan A; Meschino WS; Panabaker K; Perrier R; Provencher D; Schrader KA; Serfas K; Tomiak E; Wong N; Young SS; Gotlieb WH; Hoskins P; Kim RH;
J Med Genet; 2018 Sep; 55(9):571-577. PubMed ID: 30042185
[TBL] [Abstract][Full Text] [Related]
20. Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
McCuaig JM; Care M; Ferguson SE; Kim RH; Stockley TL; Metcalfe KA
Gynecol Oncol; 2020 Sep; 158(3):747-753. PubMed ID: 32674931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
